Clinical efficacy and drug resistance of anti-epidermalgrowth factor receptor therapy in colorectal cancer

• 来源期刊: 世界胃肠肿瘤学杂志：英文版（电子版）
• 学科: 医学
• 关键词: Colorectal cancer EPIDERMAL GROWTH factorreceptor KRAS mutation Anti-epidermal GROWTH factorreceptor antibody Drug resistance
• 年，卷（期）: 2016,（1）
• 页码范围: 1-7
• 页数: 7页
• 分类号: R

摘要

Colorectal cancer （CRC） ranked third in cancer relateddeath and its incidence has been increasing worldwide.In recent decades important therapeutic advances havebeen developed in treatment of metastatic CRC （mCRC）,such as monoclonal antibodies against epidermal growthfactor receptor （anti-EGFR）, which provided additionalclinical benefits in mCRC. However, anti-EGFR therapieshave limited usage due to approximately 95% ofpatients with KRAS mutated mCRC do not response toanti-EGFR treatment. Thus, KRAS mutation is predictiveof nonresponse to anti-EGFR therapies but it alone is nota sufficient basis to decide who should not be receivedsuch therapies because; approximately fifty percent（40%-60%） of CRC patients with wild-type KRASmutation also have poor response to anti-EGFR basedtreatment. This fact leads us to suspect that there mustbe other molecular determinants of response to anti-EGFR therapies which have not been identified yet. Currentarticle summarizes the clinical efficacy of anti-EGFRtherapies and also evaluates its resistance mechanisms.